Teva cephalon merger

June 19, On June 17,the U.

Teva cephalon merger

His parents, Dennis and Barbara, immigrated to Adelaide in with Peter and his younger sister Denise. Both gave Peter sage advice to focus on the pure science of biochemistry and not venture prematurely into the emerging field of biotechnology.

Peter and Phil Evans were sole authors on the prestigious Nature publication that announced this structure in Peter experienced the worldwide moratorium on genetic engineering first-hand at LMB, Cambridge.

Teva cephalon merger

Peter maintained close links to the MRC-LMB over the years and was invited back for sabbatical stints in andas an International Review member in and as an Alumnus for the opening of the new LMB laboratories in July There he designed and built one of the first genetic engineering suites in Australia and, with the collaboration of John Shine ANU and several Howard Florey Institute scientists, Peter cloned the relaxin gene family and was lead author on two Nature articles describing these proteins Sinceseveral companies have evaluated the human health benefits of the relaxin gene family, culminating in the announcement by Novartis that the second human relaxin gene which Peter had discovered in Serelaxin, a vasodilator reduces deaths arising from cardiac arrest and is intended for market release to the public.

IBDV, a Birnavirus, is a major pathogen of the world-wide poultry industries.

Teva Buys Cephalon For $B

The project was funded by two National Biotechnology Program grants. The IBDV team was the first to describe the total gene sequence two double stranded RNA segments of a Birnavirus and the mechanism by which the major viral genome segment translation product polyprotein is proteolytically converted to three functional viral proteins, VP2, VP3 and VP4.

Infectious bursal disease virus vaccine. Gene cloning collaborations With the expertise in gene cloning gained at Cambridge, Peter forged several collaborations with external Institutions on his return to Australia and was successful in constructing cDNA libraries and identifying and cloning several mammalian genes.

The program operated over the next 18 years to These new mutation and selection technologies, using bacterial viruses, were a revolutionary technique that enabled rapid isolation of new binding proteins to rival conventional monoclonal antibodies.

Peter was the founder and principal scientific advisor for EvoGenix which eventually merged with Absalus, listed on ASXfused with Peptech into Arana Ltdand was acquired by Cephalon Inc and then by Teva Pharmaceutical Industries Ltd Their primary application was in oncology, with the small diabodies enabling high penetration and residence at the site of tumours, ideal for radio-imaging or immunotoxin therapy.

As Director of VCB, Peter coordinated the discovery, development and translation of oncology AvibodyTM products for diagnostics and therapeutics into clinical trials. The PET images will direct and expedite the subsequent drug or radioisotope loaded therapeutic products being developed at Avipep with VCB and International partnerships.

He is frequently invited to deliver plenary lectures at International Institutes and Global Conventions. Honours, Awards and Activities.Peter John Hudson was born in Manchester, England on 3 rd August His parents, Dennis and Barbara, immigrated to Adelaide in with Peter and his younger sister Denise.

Find the latest business news on Wall Street, jobs and the economy, the housing market, personal finance and money investments and much more on ABC News. Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Cephalon, Inc. (NASDAQ: CEPH) today announced that their Boards of Directors have unanimously approved a definitive agreement under which Teva will acquire all of the outstanding shares of Cephalon for $ per share in cash, or a total enterprise value of approximately $ billion.

The article reports that Israeli company Teva Pharmaceutical Industries Ltd. outbid Valeant Pharmaceutical International Inc. to acquire Cephalon Inc.

Teva cephalon merger

Teva will purchase Cephalon for billion dollars in cash, beating the . ImmuPharma plc Regains Lupuzor Rights from Cephalon, Inc. Due to Teva Pharmaceutical Industries Limited Merger - read this article along with other careers information, tips and advice on BioSpace.

May 02,  · Shares in Cephalon jumped upon news of the transaction, gaining % or $ to $, still below the transaction price of $ Teva also opened deep in the green on Monday, trading up % or $ to $ by AM in New York, while Valeant’s stock took a big hit, dropping % or $ to $

Peter John Hudson - CSIROpedia